Menu
Search
|

Menu

Close
X

Endocyte Inc ECYT.OQ (NASDAQ Stock Exchange Global Select Market)

17.33 USD
+0.23 (+1.35%)
As of Jul 20
chart
Previous Close 17.10
Open 17.16
Volume 228,521
3m Avg Volume 474,494
Today’s High 17.66
Today’s Low 17.10
52 Week High 17.69
52 Week Low 1.17
Shares Outstanding (mil) 42.58
Market Capitalization (mil) 244.81
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.156
FY17
-1.271
FY16
-1.040
FY15
-0.986
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
3,497.27
5.73
Price to Book (MRQ)
vs sector
2.11
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-31.67
14.61
Return on Equity (TTM)
vs sector
-31.86
16.34

EXECUTIVE LEADERSHIP

John Aplin
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Michael Sherman
President, Chief Executive Officer, Director, Since 2017
Salary: $322,985.00
Bonus: $102,128.00
Michael Andriole
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Philip Low
Chief Science Officer, Director, Since 1998
Salary: $98,846.00
Bonus: $36,000.00
Michael Brinkley
Vice President - Quality, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3000 Kent Ave Ste A1-100
WEST LAFAYETTE   IN   47906

Phone: +1765.4637175

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

SPONSORED STORIES